Single-cell sequencing combined with machine learning to identify glioma biomarkers and therapeutic targets

Our prognostic model, based on the differentiation-related gene signatures, may be valuable for predicting prognosis and immunotherapy response in glioma patients. Characterizing these ubiquitination-associated features may elucidate the molecular mechanisms driving GBM progression and offer novel insights for its diagnosis and treatment. Additionally, machine learning identified four biomarkers with potential for aiding in the diagnosis and treatment of GBM.